News
-
-
BREAKING NEW GROUND | The First-Ever Guidelines for Managing α-Thalassaemia
The Thalassaemia International Federation (TIF) is proud to present the first international-level guidelines for the management of a-thalassaemia, a comprehensive and indispensable resource for health professionals, researchers and all those…
Read More » -
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | LDH Improvements Lead to Better Outcomes in Fatigue and QoL
PNH is a rare anaemia known for causing blood cell destruction, which can be shown by LDH levels. The study compared two drugs, eculizumab and ravulizumab, to see how they…
Read More » -
TIF’s NEW e-COURSE | Enhance Your Understanding of EU Health Policy
To address this need, the Thalassaemia International Federation (TIF) has launched an e-course titled ‘EU Health Policy Course’, which offers a comprehensive and up-to-the-minute overview of EU health-related policies. The…
Read More » -
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
The Conference, organized in collaboration with the Federation of Malaysia Thalassaemia Societies, the Malaysia Hematology Society and the Malaysian Association of Paediatric Haematology & Oncology, and with the support of…
Read More » -
CLINICAL NEWS | Promising Outcomes Found with Stem Cell Transplant for Fanconi Anemia-related Leukemia, MDS
Two-thirds of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) resulting from Fanconi anemia (FA) were still alive at…
Read More » -
POSITION PAPER | Strengthening the Resilience of EU Health Systems
Thalassaemia is more than just a rare condition in Europe; it is a pressing issue that requires prompt action. With shifting migration patterns and escalating healthcare costs, EU health systems…
Read More » -
THAL PALS PODCAST | New Episode on TIF’s NTDT Guidelines Out Now
Dr. Κevin Kuo, MD, MSc, Clinician Investigator, and Μrs. Laurice Levine, Thalassaemia Patient Advocate, talk to TIF’s Executive Director, Dr Androulla Eleftheriou, and Dr. Khaled Musallam, Chief Research Officer, MD,…
Read More » -
Imatinib’s Impact on Reducing Painful Episodes in Sickle Cell Disease
Currently, hydroxyurea (HU) is the only FDA-approved drug highly recommended for treating sickle cell anemia. However, its efficiency varies among patients with sickle cell disease for unknown reasons. Given the…
Read More » -
WEBINAR | Official Launch of TIF’s Nutrition Guidelines in Thalassaemia and PKD
This essential guide has been eagerly awaited by healthcare professionals and patients alike, and we are pleased to invite you to participate in the event. Date: October 13th, 2023 Time:…
Read More »